Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

News: Melanoma

Patients Show Benefit from Melanoma Drug

Friday, May 6th, 2011

On Mother’s Day 2008, Marcia Akers was expecting a traditional Mother’s Day gift from her children. Instead, she received a piercing pain, like a lightning bolt streaking down the right side of her body. The seizure resulted in a trip to a Nashville hospital where tests revealed a golf ball-size tumor in her brain. Doctors […]

Dozens at VICC Listed Among Best Doctors

Thursday, May 5th, 2011

Two popular surveys that recognize physician expertise have again included hundreds of doctors from Vanderbilt University Medical Center, including 40 involved in the care for cancer patients and their caregivers. America’s Top Doctors listed 59 Vanderbilt physicians, while Best Doctors in America included 227 Vanderbilt faculty members. One or both lists included 40 members of […]

Be Smart About the Sun

Monday, May 2nd, 2011

What is Melanoma/ Skin Cancer? Melanoma is a cancer that begins in specific type of skin cell. The skin is the body’s largest organ, and it helps protect against, heat, sunlight, injury and infection. Your skin helps control body temperature as well as stores water, fat and vitamin D. With several layers, the epidermis and […]

VICC Launches Genetic Research Tool

Friday, March 4th, 2011

Vanderbilt-Ingram Cancer Center has launched the nation’s first personalized cancer decision support tool, “My Cancer Genome,” to help physicians and researchers track the latest developments in personalized cancer medicine and connect with clinical research trials for their patients. This web-based information tool is designed to quickly educate clinicians on the rapidly expanding list of genetic […]

Have You Checked Out Cancer Connect Yet?

Thursday, February 10th, 2011

Vanderbilt-Ingram Cancer Center has joined with the national CancerConnect.com initiative to launch a new online support community for people impacted by cancer, including patients, family members, friends and advocates. Participants don’t have to be a Vanderbilt-Ingram patient or family member to join the online community. There they can share stories, ask questions and learn from […]

Share Your Stories, Art

Wednesday, January 5th, 2011

Tabula Rasa, the School of Medicine’s journal of medical humanities, is now accepting submissions for its 2010-2011 issue. The theme of this year’s journal is “Transformation: How Illness and Healing Change Us.” All submissions that meet the criteria (see below) will be featured on the Tabula Rasa website, and many of the selected submissions will […]

Call Center Operations Restored

Tuesday, January 4th, 2011

Update as of Thursday, Jan. 6: Call Center staff have been relocated to temporary locations, with phones and computers, so our service has been restored. Thanks to everyone for their patience while we addressed this unexpected situation. Kudos to our team for their dedication to finding a way to get back on line for our […]

New Online Community for Survivors

Friday, December 31st, 2010

Editor’s note: Cynthia Floyd Manley, Vanderbilt-Ingram Cancer Center’s associate director for communications, will appear on Lifetime Television’s The Balancing Act on Monday, Jan. 3, to discuss social networking for cancer survivors and caregivers. Vanderbilt-Ingram Cancer Center has joined with the national CancerConnect.com initiative to launch a new online community for people impacted by cancer. As […]

Clinical Trials in Era of Targeted Therapies

Friday, December 17th, 2010

Cousins with melanoma caused by the same genetic mutation enroll in a randomized clinical trial of a promising experimental drug that targets the mutation. Randomly assigned to different groups, one young man gets the new drug, experiences dramatic shrinkage of his tumors and is alive nine months later, while his cousin receives current therapy — […]

Clue to Melanoma Drug Resistance

Friday, December 17th, 2010

Patients with metastatic melanoma being treated with the new investigational cancer drug PLX4032 are showing strong responses, with an 80 percent anti-tumor response rate among patients whose tumors are positive for the B-RAF (V600E) gene mutation. However, in all too many cases, patients are developing resistance to the drug and their cancer is beginning to […]

Next Page »« Previous Page